Oruka Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the Annual Meeting of Stockholders held by Oruka Therapeutics, Inc. on June 2, 2026. The filing details the voting results for three proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
The following matters were voted upon at the Annual Meeting:
- Proposal 1: Election of Directors
- Lawrence Klein: 43,918,579 votes For; 63,593 votes Withheld.
- Chris Martin: 43,936,173 votes For; 45,999 votes Withheld.
- Broker non-votes: 1,267,194.
- Outcome: Both Class II directors were elected to serve until the 2029 annual meeting.
- Proposal 2: Ratification of Independent Auditor
- PricewaterhouseCoopers LLP was ratified for the fiscal year ending December 31, 2026.
- Votes For: 45,206,297; Votes Against: 39,637; Abstentions: 3,432.
- Broker non-votes: None.
- Proposal 3: Executive Compensation (Say-on-Pay)
- Non-binding advisory vote on Named Executive Officer compensation.
- Votes For: 43,033,967; Votes Against: 875,114; Abstentions: 73,091.
- Broker non-votes: 1,267,194.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. For detailed descriptions of the proposals, the filing references the definitive proxy statement filed on April 17, 2026.
Investor Verification Checklist
- Verify the total number of shares outstanding to calculate the percentage of votes cast for each proposal.
- Review the definitive proxy statement filed on April 17, 2026, for detailed biographies of the elected directors and the specific compensation metrics approved.
- Confirm the term length for the newly elected directors (Class II) extends through the 2029 annual meeting.